NZ510168A - Dry powder active agent pulmonary delivery - Google Patents

Dry powder active agent pulmonary delivery

Info

Publication number
NZ510168A
NZ510168A NZ510168A NZ51016899A NZ510168A NZ 510168 A NZ510168 A NZ 510168A NZ 510168 A NZ510168 A NZ 510168A NZ 51016899 A NZ51016899 A NZ 51016899A NZ 510168 A NZ510168 A NZ 510168A
Authority
NZ
New Zealand
Prior art keywords
particles
active agent
growth inhibitor
cyclodextrin
hygroscopic growth
Prior art date
Application number
NZ510168A
Other languages
English (en)
Inventor
Andrew Clark
Mei-Chang Kuo
Cecily Lalor
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of NZ510168A publication Critical patent/NZ510168A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
NZ510168A 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery NZ510168A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14
PCT/US1999/021109 WO2000015262A1 (en) 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery

Publications (1)

Publication Number Publication Date
NZ510168A true NZ510168A (en) 2003-09-26

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510168A NZ510168A (en) 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery

Country Status (44)

Country Link
EP (1) EP1117442A1 (is)
JP (1) JP2002524535A (is)
KR (1) KR20010075063A (is)
CN (1) CN1317977A (is)
AP (1) AP1374A (is)
AR (1) AR022090A1 (is)
AU (1) AU753014B2 (is)
BG (1) BG105430A (is)
BR (1) BR9913722A (is)
CA (1) CA2343920A1 (is)
CO (1) CO5130023A1 (is)
CZ (1) CZ2001829A3 (is)
DZ (1) DZ2892A1 (is)
EA (1) EA003476B1 (is)
EE (1) EE200100151A (is)
GE (1) GEP20043257B (is)
GT (1) GT199900156A (is)
HK (1) HK1042231A1 (is)
HN (1) HN1999000159A (is)
HR (1) HRP20010189A2 (is)
HU (1) HUP0103837A3 (is)
ID (1) ID28845A (is)
IL (2) IL141562A0 (is)
IS (1) IS5878A (is)
LT (1) LT4897B (is)
LV (1) LV12658B (is)
MA (1) MA25590A1 (is)
MY (1) MY129282A (is)
NO (1) NO20011251L (is)
NZ (1) NZ510168A (is)
OA (1) OA11781A (is)
PA (1) PA8481901A1 (is)
PE (1) PE20001061A1 (is)
PL (1) PL195574B1 (is)
SA (1) SA99200718B1 (is)
SK (1) SK3442001A3 (is)
TN (1) TNSN99173A1 (is)
TR (1) TR200101182T2 (is)
TW (1) TWI226248B (is)
UA (1) UA76085C2 (is)
UY (1) UY25711A1 (is)
WO (1) WO2000015262A1 (is)
YU (1) YU24201A (is)
ZA (1) ZA200101995B (is)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2708225A1 (en) 2004-04-23 2014-03-19 CyDex Pharmaceuticals, Inc. DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1185248B1 (en) 1999-06-09 2012-05-02 Robert E. Sievers Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
IL163685A0 (en) 2002-02-25 2005-12-18 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
JP2006513139A (ja) * 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療薬の全身性送達のための中央部気道投与
CA2511385A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EA017982B1 (ru) 2005-02-24 2013-04-30 ДИФФЬЮЖН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Фармацевтическая композиция на основе транскаротиноидов и способы лечения опухоли
KR20070110418A (ko) * 2005-03-09 2007-11-16 오노 야꾸힝 고교 가부시키가이샤 입자 및 그 입자를 함유하는 제제
DK2581078T3 (en) 2005-10-26 2015-03-02 Cydex Pharmaceuticals Inc Sulfoalkylætercyclodekstrinsammensætninger and processes for the preparation thereof
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2008021451A2 (en) * 2006-08-14 2008-02-21 Aktiv-Dry Llc Human-powered dry powder inhaler and dry powder inhaler compositions
JP5315056B2 (ja) * 2006-10-25 2013-10-16 大日本住友製薬株式会社 固結抑制粒状製剤
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
EP2146948A4 (en) 2007-04-13 2010-08-04 Diffusion Pharmaceuticals Llc USE OF BIPOLAR TRANS-CAROTINOIDES AS PRE-TREATMENT AND TREATMENT OF PERIPHERAL VASCULAR DISEASE
AU2008319225B2 (en) 2007-10-31 2016-09-29 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
ES2661215T3 (es) 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
EP2575487B1 (en) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
WO2013164380A1 (en) 2012-05-03 2013-11-07 Janssen R&D Ireland Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
EP3432929A4 (en) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC USE OF BIPOLAR TRANSCAROTINOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR THE TREATMENT OF CANCER
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
ES2177544T3 (es) * 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ATE287257T1 (de) * 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2708225A1 (en) 2004-04-23 2014-03-19 CyDex Pharmaceuticals, Inc. DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin
EP3520779A1 (en) 2004-04-23 2019-08-07 CyDex Pharmaceuticals, Inc. Dpi formulation containing sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
AR022090A1 (es) 2002-09-04
CN1317977A (zh) 2001-10-17
CO5130023A1 (es) 2002-02-27
PE20001061A1 (es) 2000-10-08
IS5878A (is) 2001-03-05
SK3442001A3 (en) 2001-11-06
HN1999000159A (es) 1999-11-11
UY25711A1 (es) 1999-11-17
GEP20043257B (en) 2004-06-25
ZA200101995B (en) 2002-03-11
EE200100151A (et) 2002-06-17
SA99200718B1 (ar) 2006-11-04
YU24201A (sh) 2003-08-29
LV12658B (lv) 2001-09-20
UA76085C2 (en) 2006-07-17
TNSN99173A1 (fr) 2005-11-10
AU753014B2 (en) 2002-10-03
BG105430A (en) 2001-12-29
LT4897B (lt) 2002-02-25
BR9913722A (pt) 2001-05-29
HK1042231A1 (zh) 2002-08-09
MY129282A (en) 2007-03-30
LT2001021A (en) 2001-11-26
WO2000015262A1 (en) 2000-03-23
KR20010075063A (ko) 2001-08-09
IL141562A (en) 2007-07-24
OA11781A (en) 2005-07-26
PL195574B1 (pl) 2007-10-31
NO20011251L (no) 2001-04-17
AU6039799A (en) 2000-04-03
PL346768A1 (en) 2002-02-25
NO20011251D0 (no) 2001-03-13
AP1374A (en) 2005-02-28
TWI226248B (en) 2005-01-11
CA2343920A1 (en) 2000-03-23
HRP20010189A2 (en) 2005-04-30
AP2001002093A0 (en) 2001-03-31
PA8481901A1 (es) 2002-04-25
ID28845A (id) 2001-07-05
JP2002524535A (ja) 2002-08-06
DZ2892A1 (fr) 2003-12-15
CZ2001829A3 (cs) 2001-09-12
LV12658A (lv) 2001-05-20
MA25590A1 (fr) 2002-12-31
EP1117442A1 (en) 2001-07-25
EA200100300A1 (ru) 2001-10-22
HUP0103837A3 (en) 2002-11-28
HUP0103837A2 (hu) 2002-05-29
IL141562A0 (en) 2002-03-10
GT199900156A (es) 2001-03-07
TR200101182T2 (tr) 2001-09-21
EA003476B1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
AU753014B2 (en) Dry powder active agent pulmonary delivery
JP4859320B2 (ja) 改良された分散性を有する乾燥粉末組成物
US5855913A (en) Particles incorporating surfactants for pulmonary drug delivery
US6921528B2 (en) Highly efficient delivery of a large therapeutic mass aerosol
CA2336139C (en) Large porous particles emitted from an inhaler
Hamishehkar et al. The role of carrier in dry powder inhaler
AU2003230689B2 (en) Inhalable sustained therapeutic formulations
JP2003513031A5 (is)
US7754242B2 (en) Inhalable sustained therapeutic formulations
US20220133708A1 (en) Inhalable sustained therapeutic formulations
JP2005520847A (ja) 肺投与用ｈＧＨ（ヒト成長ホルモン）製剤
MXPA01002649A (en) Dry powder active agent pulmonary delivery
Batycky et al. The development of large porous particles for inhalation drug delivery

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)